SUPPLEMENTARY FINANCIAL STATEMENT INFORMATION (Tables)

12 Months Ended

Dec. 31, 2015

SUPPLEMENTARY FINANCIAL STATEMENT INFORMATION [Abstract]

Schedule of Other Current Liabilities

Current liabilities:

	December 31,
	2014		2015
Director fees	$	11	$	25
Trade payables		29		41
Accrued expenses and other		144		160
	$	184	$	226

Schedule of Financial Income (Expenses), Net

Financial expenses, net

	Year ended December 31,
	2013		2014			2015
Financial expenses:
Loss from change in fair value of investment in BioCancell and sale of BioCancell shares	$	-	$	(245	)	$	(36	)
Other		-		(7	)		(2	)
		-	$	(252	)	$	(38	)
Financial income:
Income from change in fair value of investment in BioCancell and sale of BioCancell shares		574		-			-
Other		5		12			9
		579		12			9
	$	579	$	(240	)	$	(29	)